Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer

Nathan, Paul; Zweifel, Martin; Padhani, Anwar R; Koh, Dow-Mu; Ng, Matthew; Collins, David J; Harris, Adrian; Carden, Craig; Smythe, Jon; Fisher, Nita; Taylor, N Jane; Stirling, J James; Lu, Shiao-Ping; Leach, Martin O; Rustin, Gordon J S; Judson, Ian (2012). Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer. Clinical cancer research, 18(12), pp. 3428-39. Philadelphia, Pa.: American Association for Cancer Research 10.1158/1078-0432.CCR-11-3376

Full text not available from this repository. (Request a copy)

The vascular disrupting agent (VDA) combretastatin A4 phosphate (CA4P) induces significant tumor necrosis as a single agent. Preclinical models have shown that the addition of an anti-VEGF antibody to a VDA attenuates the revascularization of the surviving tumor rim and thus significantly increases antitumor activity.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Zweifel, Martin

ISSN:

1078-0432

Publisher:

American Association for Cancer Research

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:36

Last Modified:

11 Jul 2018 17:13

Publisher DOI:

10.1158/1078-0432.CCR-11-3376

PubMed ID:

22645052

Web of Science ID:

000307502100023

URI:

https://boris.unibe.ch/id/eprint/14285 (FactScience: 221161)

Actions (login required)

Edit item Edit item
Provide Feedback